Background Immune checkpoint blockade (ICB) therapy has revolutionized the treatment of
lung squamous cell carcinoma (LUSC). However, a significant proportion of patients with …

Non-Small Cell Lung Cancer (NSCLC) is a disease with high morbidity and mortality, which
has sex-related differences in prognosis and immunotherapy efficacy. However, the …

Immunotherapy is a mainstay of non-small cell lung cancer (NSCLC) management. While
tumor mutational burden (TMB) correlates with response to immunotherapy, little is known …

Objective Current predictive biomarkers for PD-1 (programmed cell death protein 1)/PD-L1
(programmed death-ligand 1)-directed immunotherapy in non-small cell lung cancer …

BACKGROUND. Immune checkpoint blockade improves survival in a subset of patients with
non–small-cell lung cancer (NSCLC), but robust biomarkers that predict response to PD-1 …

Introduction The combination of programmed cell death protein-1 or programmed death-
ligand 1 immune checkpoint blockade and chemotherapy has revolutionized the treatment …

Characterizing the molecular immune subtype and micro-environment of lung cancer is
necessary to understand immunogenic interactions between infiltrating immune and stromal …

Non-small cell lung cancer (NSCLC) is the most widely distributed tumor in the world, and its
immunotherapy is not practical. Neutrophil is one of a tumor's most abundant immune cell …

The impact of the tumor immune microenvironment on overall survival in non‐small cell lung
cancer (NSCLC) has been studied, but there is little information on its relevance for risk of …

Several clinical trials have shown the safety and effectiveness of PD-1/PD-L1 inhibitors in
neoadjuvant therapy in resectable non-small cell lung cancer (NSCLC). However, 18–83 …